Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1980 Nov;35(11):856-8.
doi: 10.1136/thx.35.11.856.

Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions

Clinical Trial

Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions

J W Millar et al. Thorax. 1980 Nov.

Abstract

Twenty-one patients with proven recurrent malignant pleural effusions were randomly allocated to treatment groups receiving either intrapleural Corynebacterium parvum in a dose of 7 mg or intrapleural mustine (20 mg). The designated intrapleural therapy was repeated on one occasion if further pleural aspiration was required. Corynebacterium parvum (nine patients) proved superior to mustine (12 patients) in suppressing the reaccumulation of pleural fluid, and was associated with only minimal side-effects of fever and nausea in two patients. Mustine caused marked nausea and vomiting in almost all patients. Three of the four patients who were deemed "failures" after mustine therapy had complete suppression of pleural fluid reaccumulation after a single dose of C parvum, the survival of the fourth being too short to assess a response adequately. There were no failures in the C parvum treated group. Corynebacterium parvum appears to be an effective, well-tolerated agent in the management of recurrent pleural effusions. The relative contribution of its potent immunological stimulant effect to its mode of action remains uncertain.

PubMed Disclaimer

References

    1. Thorax. 1969 Jan;24(1):69-73 - PubMed
    1. Nouv Presse Med. 1972 Jan 1;1(1):19-23 - PubMed
    1. Br Med J. 1978 Feb 11;1(6109):338-40 - PubMed
    1. Lancet. 1979 Apr 21;1(8121):872 - PubMed
    1. Scand J Respir Dis. 1979 Aug;60(4):197-205 - PubMed

Substances

LinkOut - more resources